Radiopharm Theranostics (RAD) KOL Event summary

Introduction and agenda

• Focused on the evolving prostate cancer treatment landscape, highlighting unmet needs and the emergence of B7-H3 as a novel target.

• Featured presentations by leading experts, followed by a moderated Q&A session.

KOL background and credentials

• Dr. Oliver Sartor: Renowned oncologist, expert in prostate cancer, led multiple clinical trials resulting in FDA approvals, with over 500 peer-reviewed articles.

• Dr. David Piwnica-Worms: Chair and Professor at MD Anderson, expert in cancer imaging and preclinical development of B7-H3 targeting assets.

• Dr. Hans David Ulmert: Associate Professor at UCLA, directs the Preclinical Theranostics Program, specializing in targeted therapies and molecular imaging for prostate cancer.

Market insights and analysis

• Prostate cancer management has shifted to include genetics, molecular imaging, AI, and targeted radiopharmaceuticals.

• High B7-H3 protein expression in solid tumors is linked to poor prognosis and significant unmet need.

• Despite advances, metastatic castration-resistant prostate cancer remains fatal, with current therapies offering limited survival benefits.

• Pluvicto (PSMA-targeted radioligand) has improved outcomes but does not cure, and most patients eventually relapse.

• The company’s pipeline includes one Phase 2 and three Phase 1 trials across various solid tumor cancers, including lung, breast, and brain metastases.